- |||||||||| Rituxan (rituximab) / Roche
Deep B Cell Tissue Depletion Following Anti-CD19 CART Cells Therapy (Room 144ABC; In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1040;
We performed consecutive ultrasound-guided inguinal lymph node (LN) biopsies in 5 patients with AIDs (3 SLE and 2 SSc) before and after CD19-CAR T-cell therapy and compared them with inguinal LN biopsies from 5 patients (2 SSc and 3 granulomatosis with polyangiitis; GPA) collected after rituximab (RTX) treatment... This study demonstrates for the first time that the CD19-CAR T-cell therapy induces a complete B-cell depletion in secondary lymphoid tissues of AID patients and highlights the importance of tissue analysis after B-cell depleting therapy.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Aggressive Mantle Cell Lymphoma with Neurolymphomatosis and Cutaneous Infiltration: First Case Report and Review of Literature () - Nov 29, 2022 - Abstract #ASH2022ASH_7404;
He received treatment with dexamethasone and PLEX with no improvement...Most cases were treated with systemic chemotherapy with R-CHOP and high dose Methotrexate...MRI is the diagnostic modality of choice, which was instrumental in establishing diagnosis in our case and further workup was not felt necessary. Novel CART-cell therapy and consolidative therapies such as high dose chemotherapy followed by stem cell transplant (HDC- ASCT) should be considered in appropriate cases, as we intended in our case after disease stabilization.
- |||||||||| lenalidomide / Generic mfg.
Journal, CAR T-Cell Therapy: Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia. (Pubmed Central) - Jul 15, 2022
In a Rag2γ-based xenograft model of CLL, we demonstrated that, when combined with low-dose lenalidomide, CD23.CAR T cells efficiently migrated to leukemic sites and delayed disease progression when compared to CD23.CAR T cells given with rhIL-2. These observations underline the therapeutic potential of this novel CAR-based combination strategy in CLL.
- |||||||||| THE EXPRESSION OF CD268 HELPS TO DISTINGUISH CHRONIC LYMPHOCYTIC LEUKEMIA FROM OTHER MATURE B-CELL LYMPHOMAS (ePoster Area [VIRTUAL]) - Jan 30, 2022 - Abstract #EBMT2022EBMT_1182;
The combination of immune markers CD5, CD23, CD200 and CD79b detected by multi-parameter flow cytometry can effectively distinguish CLL lymphoma from non-CLL lymphoma, and the new marker CD268 provides a new diagnostic basis for differential diagnosis. Moreover, it is highly expressed in most mature B-cell lymphomas and is expected to be an effective therapeutic target.
- |||||||||| docetaxel / Generic mfg.
[VIRTUAL] FOLLICULAR DENDRITIC CELL SARCOMA: CASE REPORT () - Oct 27, 2021 - Abstract #HEMO2021HEMO_804;
On examination he presented a large lymph node conglomerate of approximately 10 cm in length, which affected the numerous lymph node levels: submandibular, superior jugulo-carotid, middle jugulo-carotid and jugulo-omo -hyoid. Radical neck dissection was performed on the right. The result of the immunohistochemical study was follicular dendritic cell sarcoma. The diagnosis corresponds to a lymph node with a neoplasm consisting of atypical cells, with a vesicular nucleus and eosinophilic cytoplasm, positive for CD21, CD23 and, in rare cells, for CD15. Follicular dendritic cell sarcoma (SCDF) is a rare malignant lymphoid neoplasm that differentiates into follicular dendritic cells, these cells, if healthy, play an essential role in the presentation of antigens to B cells and in the regulation of reactions in the germinal centers. It especially affects lymph nodes, but it can also occur in extranodal sites. SCDF is a lesion that occurs mainly in adults and presents as a slow-growing painless cervical lymphadenopathy without associated systemic symptoms. Such malignant neoplasm prefers the following extranodal sites: soft palate, tonsils, spleen, gastrointestinal tract and soft tissues. The diagnosis of SCDF is established based on morphological and immunohistochemical findings. Furthermore, the clinical presentation of patients is highly variable as the disease may heterogeneously involve nodal and extranodal sites throughout the body. Neoplastic cells have an immunophenotype identical to that of normal follicular dendritic cells, with CD21, CD23 and/or CD35 receptors being the most specific markers. Microscopically, this neoplasm is composed of spindle-shaped or oval cells arranged in a storiform or swirling arrangement. Tumor cells have abundant eosinophilic cytoplasm, in part fibrillar, and occasionally, especially in recurrent tumors, marked nuclear pleomorphism is observed. The reported patient will be referred to start chemotherapy. The ideal treatment is not yet well defined, but the combined approach between surgery, chemotherapy and/or radiotherapy has become a commonly used modality. The CHOP or ICE regimen has also been used and, recently, gemcitabine and docetaxel have shown promising Results in the treatment of SCDF. Due to limited data on cytogenetics there is no evidence of agents with confirmed efficacy, however, there are some potential targets that should be studied for a better understanding of the neoplasm, such as epidermal growth factor receptor, function alterations in NFKBIA and CDKN2A and copy number gains on chromosome 9p24.
- |||||||||| Clinical, Journal: Phenotypic Switch of Human Peritoneal Macrophages during Childhood. (Pubmed Central) - Oct 7, 2021
This is the first study showing that lineage marker expression of peritoneal macrophages in neonates differs from that in adults. The knowledge about neonatal tissue resident macrophages might help to understand their complex interaction and to use specific macrophage properties for therapeutic approaches.
- |||||||||| Journal: Sarcoma de células dendríticas foliculares. Informe de un caso. (Pubmed Central) - Oct 1, 2021
The knowledge about neonatal tissue resident macrophages might help to understand their complex interaction and to use specific macrophage properties for therapeutic approaches. Follicular dendritic cell sarcoma is rare and its global survival is short.
|
